Engage With Us
We are the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. Since our founding in 1996, we have been pioneers in the royalty market, collaborating with innovators from academic institutions and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies.
APPROVED PRODUCT ROYALTY MONETIZATION
The biopharmaceutical industry is undergoing a period of strong growth and unprecedented innovation. We intend to further this innovation by acquiring royalties on leading biopharmaceutical products, particularly those that are early in their life cycles.
lnk Royalty Monetization
DEVELOPMENT CANDIDATES
We seek to acquire royalties on innovative product candidates in the late-stages of clinical development. We collaborate directly with innovators to acquire a new synthetic royalty, monetize an existing royalty or provide capital to an innovator to co-fund clinical development of a product candidate in exchange for a royalty.
lnk RD Partnership
M&A
We take a flexible approach to acquisitions. In biopharmaceutical acquisitions, the focus of an acquirer is typically on strategic assets over which the target has operational control, rather than on passive financial assets such as royalties. We can partner with strategic acquirers which buy companies that own both strategic assets and passive royalties.